transient receptor potential cation channel subfamily V member 4Genealiases: BCYM3 · CMT2C · HMSN2C · OTRPC4 · SMAL · SPSMA
Q-omics provides the consensus-scored TRPV4 profile across patient tissues and cancer cell-line models. TRPV4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRPV4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TRPV4 RNA expression shows 21,073 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where TRPV4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPV4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPV4 survival associations across molecular data types. TRPV4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPV4 RNA expression–survival associations across cancer types. High TRPV4 expression shows unfavorable associations in UVM and OV, but favorable associations in HNSC, KIRP, KIRC and KICH. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRPV4 RNA expression.
This table summarizes TRPV4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TRPV4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPV4 shows lower tumor expression in KIRP, KICH and LIHC and higher tumor expression in COAD, LUSC and READ. The COAD box plot shows higher TRPV4 RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with TRPV4 in patient tissues and cancer cell lines. In patient samples, TRPV4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPV4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
